On October 10, 2025, Novo Nordisk announced it is winding down its cell therapy division, which had been working on a potential cure for diabetes. This decision is part of a global restructuring effort under new CEO Mike Doustdar.
The closure of this division will impact approximately 250 jobs, reflecting a strategic reallocation of resources within the company. This move indicates a shift in research priorities and a focus on other growth areas.
While the cell therapy division aimed at a diabetes cure, its closure suggests a re-evaluation of investment in this specific technology. The company is streamlining operations to prioritize investments where they are expected to have the most impact.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.